These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23263177)

  • 1. Commentary: European Medicines Agency recommends approval of a broadly protective vaccine against serogroup B meningococcal disease.
    Granoff DM
    Pediatr Infect Dis J; 2013 Apr; 32(4):372-3. PubMed ID: 23263177
    [No Abstract]   [Full Text] [Related]  

  • 2. A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?
    Martin NG; Snape MD
    Expert Rev Vaccines; 2013 Aug; 12(8):837-58. PubMed ID: 23984957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meningococcal group B vaccines.
    Findlow J
    Hum Vaccin Immunother; 2013 Jun; 9(6):1387-8. PubMed ID: 23732894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two meningococcal B vaccines receive FDA 'breakthrough therapy' designation.
    Riedmann EM
    Hum Vaccin Immunother; 2014; 10(6):1428-9. PubMed ID: 25396230
    [No Abstract]   [Full Text] [Related]  

  • 5. In Brief: New meningococcal serogroup B vaccination recommendations.
    Med Lett Drugs Ther; 2020 Nov; 62(1612):191-192. PubMed ID: 33443493
    [No Abstract]   [Full Text] [Related]  

  • 6. New frontiers in meningococcal vaccines.
    Anderson AS; Jansen KU; Eiden J
    Expert Rev Vaccines; 2011 May; 10(5):617-34. PubMed ID: 21604983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of a Serogroup B and C Meningococcal Vaccine Developed in Cuba.
    Ochoa-Azze RF; García-Imía L; Vérez-Bencomo V
    MEDICC Rev; 2018 Jul; 20(3):22-29. PubMed ID: 31242158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An effective serogroup B meningococcal vaccine.
    Domínguez F; Menéndez J; Ochoa R
    Vaccine; 2006 Nov; 24(49-50):7025-6. PubMed ID: 16879900
    [No Abstract]   [Full Text] [Related]  

  • 9. Development of a vaccine against serogroup B has been the main scientific challenge. Preface.
    Rappuoli R; Pizza M; Black S; Moxon ER
    Vaccine; 2012 May; 30 Suppl 2():B1-2. PubMed ID: 22607893
    [No Abstract]   [Full Text] [Related]  

  • 10. Introduction of a second MenB vaccine into Europe - needs and opportunities for public health.
    Findlow J; Nuttens C; Kriz P
    Expert Rev Vaccines; 2019 Mar; 18(3):225-239. PubMed ID: 30821535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.
    Pouwels KB; Hak E; van der Ende A; Christensen H; van den Dobbelsteen GP; Postma MJ
    Hum Vaccin Immunother; 2013 May; 9(5):1129-38. PubMed ID: 23406816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.
    Frosi G; Biolchi A; Lo Sapio M; Rigat F; Gilchrist S; Lucidarme J; Findlow J; Borrow R; Pizza M; Giuliani MM; Medini D
    Vaccine; 2013 Oct; 31(43):4968-74. PubMed ID: 23954380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protecting UK adolescents and adults against meningococcal serogroup B disease.
    Vyse A; Ellsbury G; Madhava H
    Expert Rev Vaccines; 2018 Mar; 17(3):229-237. PubMed ID: 29374982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging experience with meningococcal serogroup B protein vaccines.
    Toneatto D; Pizza M; Masignani V; Rappuoli R
    Expert Rev Vaccines; 2017 May; 16(5):433-451. PubMed ID: 28375029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine profile of 4CMenB: a four-component Neisseria meningitidis serogroup B vaccine.
    Esposito S; Principi N
    Expert Rev Vaccines; 2014 Feb; 13(2):193-202. PubMed ID: 24393061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Group B meningococcal vaccine science and policy.
    Drysdale SB; Pollard AJ
    J Infect; 2015 Jun; 71 Suppl 1():S15-20. PubMed ID: 25917798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact.
    Christensen H; Hickman M; Edmunds WJ; Trotter CL
    Vaccine; 2013 May; 31(23):2638-46. PubMed ID: 23566946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand.
    Arnold R; Galloway Y; McNicholas A; O'Hallahan J
    Vaccine; 2011 Sep; 29(40):7100-6. PubMed ID: 21803101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent developments in vaccines to prevent meningococcal serogroup B infections.
    Vermont CL; van den Dobbelsteen GP; de Groot R
    Curr Opin Mol Ther; 2003 Feb; 5(1):33-8. PubMed ID: 12669468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neisseria meningitidis serogroup B bivalent factor H binding protein vaccine.
    Brendish NJ; Read RC
    Expert Rev Vaccines; 2015 Apr; 14(4):493-503. PubMed ID: 25703792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.